Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain Therapeutics
Credit: Gain Therapeutics
Minoryx Therapeutics and Gain Therapeutics announce today the spin off of the Minoryx Site-directed Enzyme Enhancement Therapy (SEE-Tx) platform into Gain Therapeutics, a new company that will focus on using this platform to identify the next generation of non-competitive pharmacological chaperones.
Gain Therapeutics, funded by private Swiss investors and by the TiVenture fund has its headquarters in Lugano (Switzerland), with a branch operating from Barcelona (Spain). Researchers from the Minoryx laboratory at the Barcelona Science Park joined the new spin-off, under the scientific management of Dr Xavier Barril, ICREA researcher and co-founder of Minoryx Therapeutics, inventor of the technology.
This new spin-off is part of Minoryx’s business strategy, in order to concentrate the company's efforts on the clinical candidate MIN-102.
“This deal validates the SEE-Tx platform and its great potential for identifying a new generation of pharmacological chaperones with improved properties,” said Dr Marc Martinell, co-founder and CEO of Minoryx Therapeutics. “It will also allow Minoryx to focus on its clinical candidate, MIN-102, which is now in phase II/III clinical trials for the treatment of X-linked adrenoleukodystrophy and in preclinical development for other orphan CNS diseases.”
“We are delighted to build on the excellent work done by Minoryx’s team. Using the SEE-Tx platform, it has already identified molecules that have the potential to become novel therapies for the treatment of several devastating rare diseases,” said Dr Lorenzo Leoni, managing partner of TiVenture and ad-interim CEO of Gain Therapeutics. “We will invest in the further development of these molecules that should lead to the identification of clinical candidates in at least two independent programs. We are also happy to strengthen the cooperation between Barcelona and southern Switzerland, two regions with high innovation potential in the biomedical field.”
Algorithm Speeds Up Medical Image Analysis 1000 TimesNews
Medical image registration is a common technique that involves overlaying two images, such as magnetic resonance imaging (MRI) scans, to compare and analyze anatomical differences in great detail. Researchers have described a machine-learning algorithm that can register brain scans and other 3-D images more than 1,000 times more quickly using novel learning techniques.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.